Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Out-Of-Hospital Cardiac Arrest, Pneumonia

In brief

Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.

Key facts

Study ID

NCT04999592

Run by

David J. Gagnon

People needed

53

Starts

2021-08-20

Expected to finish

2024-11-01

Last updated by the study team

2025-04-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age
• Comatose (do not follow simple verbal commands)
• Have any initial heart rhythm (shockable or non-shockable)
• OHCA including the emergency department

You may not qualify if…

• Name on opt-out list
• In-hospital cardiac arrest
• Interval >6 hours from ICU admission to study drug receipt
• Preexisting terminal disease making 180-day survival unlikely
• Refused informed consent
• Emergent coronary artery bypass grafting
• Anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or penicillins)
• Under legal guardianship or prisoner
• Known colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococcus (VRE)
• Clinical bacterial infection prior to hospital admission defined as any one of the following:
• Infectious prodrome preceding OHCA
• Active course of antibiotics for infection prior to admission
• Active infection documented in the electronic medical record
• Family or surrogate endorsement of an active infection

Where it is running

• Maine Medical Center — Portland, Maine, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.